organization · Reporting owner
Sumitomo Pharma Co., Ltd.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Urovant Sciences Ltd.UROV · Entity 140739 | See Footnote (1) | February 19, 2020 | February 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Urovant Sciences Ltd.
Report date February 19, 2020 · Filed February 21, 2020
Jointly reported with Sumitomo Chemical Co., Ltd., Sumitovant Biopharma Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 22,963,263 |
Last balance in matching sequence
After 2020-02-19 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-02-19 · Purchase · Acquired 12,873 · Balance 22,872,886 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Row 2 · 2020-02-19 · Purchase · Acquired 15,165 · Balance 22,888,051 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Row 3 · 2020-02-19 · Purchase · Acquired 75,212 · Balance 22,963,263 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Jointly reported with Sumitomo Chemical Co., Ltd., Sumitovant Biopharma Ltd.
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 45,798,176 |
Reported balance
After 2023-03-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-03-10 · Purchase · Acquired 51,599,200 · Balance 45,798,176 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of Myovant Sciences Ltd. (the "Issuer") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. F2: (Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes. F3: Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of Myovant Sciences Ltd. (the "Issuer") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto.
F2: (Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes.
F3: Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
Roivant Sciences Ltd.
Report date June 22, 2023 · Filed June 26, 2023
Jointly reported with Sumitomo Chemical Co., Ltd.
Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee footnote | 71,251,083 |
Reported balance
After 2023-06-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-06-22 · Sale · Disposed 15,116,277 · Balance 71,251,083 F1: The sale reported on this Form 4 was effected pursuant to a privately negotiated transaction between Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) ("Sumitomo Pharma") and four purchasers. In connection with the transaction, Sumitomo Pharma entered into a customary lock-up agreement with Roivant Sciences Ltd. ("Roivant") covering the common shares that continue to be beneficially owned by Sumitomo Pharma following the transaction, which lock-up agreement is effective through February 29, 2024.The buyers also entered into customary lock-up agreements with Roivant covering the common shares acquired in the transaction, which lock-up agreements are effective through February 29, 2024. F2: Sumitomo Pharma directly owns 71,251,083 Common Shares. Sumitomo Pharma is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Pharma owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a privately negotiated transaction between Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) ("Sumitomo Pharma") and four purchasers. In connection with the transaction, Sumitomo Pharma entered into a customary lock-up agreement with Roivant Sciences Ltd. ("Roivant") covering the common shares that continue to be beneficially owned by Sumitomo Pharma following the transaction, which lock-up agreement is effective through February 29, 2024.The buyers also entered into customary lock-up agreements with Roivant covering the common shares acquired in the transaction, which lock-up agreements are effective through February 29, 2024.
F2: Sumitomo Pharma directly owns 71,251,083 Common Shares. Sumitomo Pharma is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Pharma owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2023 Filed Jun 26, 2023 20:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 15,116,277 | $8.60 | $129,999,982.20 |
DisclosureSEC source: 0000899243-23-016487 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Sumitomo Pharma Co., Ltd. · CIK 0001446601 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,251,083 F1 · kind: The sale reported on this Form 4 was effected pursuant to a privately negotiated transaction between Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) ("Sumitomo Pharma") and four purchasers. In connection with the transaction, Sumitomo Pharma entered into a customary lock-up agreement with Roivant Sciences Ltd. ("Roivant") covering the common shares that continue to be beneficially owned by Sumitomo Pharma following the transaction, which lock-up agreement is effective through February 29, 2024.The buyers also entered into customary lock-up agreements with Roivant covering the common shares acquired in the transaction, which lock-up agreements are effective through February 29, 2024. F2 · ownership.nature: Sumitomo Pharma directly owns 71,251,083 Common Shares. Sumitomo Pharma is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Pharma owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:17 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares | 51,599,200 | $27.00 | $1,393,178,400.00 |
DisclosureSEC source: 0000899243-23-007864 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Sumitomo Pharma Co., Ltd. · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,798,176 F1 · shares: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of Myovant Sciences Ltd. (the "Issuer") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. F2 · shares: (Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes. F1 · balance_after: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of Myovant Sciences Ltd. (the "Issuer") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. F2 · balance_after: (Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes. F3 · ownership.nature: Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 11:15 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | OtherOption (Right to Acquire) · Derivative | 1 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007110 · doc4.xml · derivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Sumitomo Pharma Co., Ltd. · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1 Underlying: Common Shares · 4,243,005 shares Expires 2023-03-30 F3 · security: Contemporaneously with the Share Return, Roivant agreed to grant Sumitovant an option (the "Option") to purchase a number of Common Shares then owned by Roivant up to 4,243,005 Common Shares, at a price equal to $27.00 per Common Share. The Option may be exercised by Sumitovant at any time during the period beginning on March 3, 2023 and ending on March 30, 2023. F3 · derivative.expiration_date: Contemporaneously with the Share Return, Roivant agreed to grant Sumitovant an option (the "Option") to purchase a number of Common Shares then owned by Roivant up to 4,243,005 Common Shares, at a price equal to $27.00 per Common Share. The Option may be exercised by Sumitovant at any time during the period beginning on March 3, 2023 and ending on March 30, 2023. F3 · derivative.underlying_shares: Contemporaneously with the Share Return, Roivant agreed to grant Sumitovant an option (the "Option") to purchase a number of Common Shares then owned by Roivant up to 4,243,005 Common Shares, at a price equal to $27.00 per Common Share. The Option may be exercised by Sumitovant at any time during the period beginning on March 3, 2023 and ending on March 30, 2023. F2 · ownership.nature: Sumitovant directly owns 45,798,176 Common Shares following the Share Return. Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma, which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 11:15 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | OtherCommon Shares | 4,243,005 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007110 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Sumitomo Pharma Co., Ltd. · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,798,176 F1 · kind: On March 3, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") voluntarily returned to Roivant Sciences Ltd., a Bermuda exempted company limited by shares ("Roivant"), for no consideration, 4,243,005 common shares, par value $0.000017727 per share (each, a "Common Share") of Myovant Sciences Ltd. (the "Issuer") subject to that certain Share Return Agreement, dated as of December 27, 2019, by and among Sumitovant, Roivant and Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma") (the "Share Return"). In addition, Sumitovant, Sumitomo Pharma and Roivant agreed that, in the event that the Agreement and Plan of Merger, dated as of October 23, 2022 (as it may be amended from time to time in accordance with its terms, the "Merger Agreement"), by and among the Issuer, Sumitovant, Zeus Sciences Ltd. and, solely with respect to Article IX and Annex A of the Merger Agreement, Sumitomo Pharma, is terminated in accordance with its terms, Roivant will return such Common Shares to Sumitovant. F1 · balance_after: On March 3, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") voluntarily returned to Roivant Sciences Ltd., a Bermuda exempted company limited by shares ("Roivant"), for no consideration, 4,243,005 common shares, par value $0.000017727 per share (each, a "Common Share") of Myovant Sciences Ltd. (the "Issuer") subject to that certain Share Return Agreement, dated as of December 27, 2019, by and among Sumitovant, Roivant and Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma") (the "Share Return"). In addition, Sumitovant, Sumitomo Pharma and Roivant agreed that, in the event that the Agreement and Plan of Merger, dated as of October 23, 2022 (as it may be amended from time to time in accordance with its terms, the "Merger Agreement"), by and among the Issuer, Sumitovant, Zeus Sciences Ltd. and, solely with respect to Article IX and Annex A of the Merger Agreement, Sumitomo Pharma, is terminated in accordance with its terms, Roivant will return such Common Shares to Sumitovant. F2 · ownership.nature: Sumitovant directly owns 45,798,176 Common Shares following the Share Return. Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma, which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 20,677 | $22.85 | $472,382.61 |
DisclosureSEC source: 0000899243-21-038387 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 50,041,181 F1 · shares: This acquisition of a total of 20,677 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $22.54 to $23.51 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 50,041,181 shares of Common Stock following the acquisition on September 28, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 2,232 | $24.86 | $55,486.18 |
DisclosureSEC source: 0000899243-21-038083 · doc4.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 50,020,504 F4 · shares: This acquisition of a total of 48,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F7 · price: The transaction was executed in multiple trades ranging from $24.76 to $24.95 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 50,020,504 shares of Common Stock following the acquisition on September 27, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 45,768 | $24.19 | $1,106,903.66 |
DisclosureSEC source: 0000899243-21-038083 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 50,018,272 F4 · shares: This acquisition of a total of 48,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $23.73 to $24.65 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 50,020,504 shares of Common Stock following the acquisition on September 27, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 36,000 | $23.40 | $842,547.60 |
DisclosureSEC source: 0000899243-21-038083 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,972,504 F1 · shares: This acquisition of a total of 36,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $23.00 to $23.68 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,972,504 shares of Common Stock following the acquisition on September 24, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 5,311 | $23.49 | $124,747.42 |
DisclosureSEC source: 0000899243-21-037631 · doc4.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,936,504 F4 · shares: This acquisition of a total of 54,778 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F7 · price: The transaction was executed in multiple trades ranging from $23.42 to $23.50 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,936,504 shares of Common Stock following the acquisition on September 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 49,467 | $23.01 | $1,138,468.16 |
DisclosureSEC source: 0000899243-21-037631 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,931,193 F4 · shares: This acquisition of a total of 54,778 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $22.41 to $23.40 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,936,504 shares of Common Stock following the acquisition on September 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 84,018 | $21.96 | $1,845,010.07 |
DisclosureSEC source: 0000899243-21-037631 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,881,726 F1 · shares: This acquisition of a total of 84,018 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $21.54 to $22.48 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,881,726 shares of Common Stock following the acquisition on September 22, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 43,000 | $22.48 | $966,450.80 |
DisclosureSEC source: 0000899243-21-037114 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,797,708 F4 · shares: This acquisition of a total of 43,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $22.17 to $22.77 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,797,708 shares of Common Stock following the acquisition on September 21, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 38,273 | $22.10 | $845,668.73 |
DisclosureSEC source: 0000899243-21-037114 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,754,708 F1 · shares: This acquisition of a total of 38,273 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $21.80 to $22.36 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,754,708 shares of Common Stock following the acquisition on September 20, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 37,913 | $22.79 | $864,105.51 |
DisclosureSEC source: 0000899243-21-036597 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,716,435 F4 · shares: This acquisition of a total of 37,913 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $22.43 to $23.19 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,716,435 shares of Common Stock following the acquisition on September 17, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $21.75 | $1,087,550.00 |
DisclosureSEC source: 0000899243-21-036597 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,678,522 F1 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $21.24 to $22.19 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,678,522 shares of Common Stock following the acquisition on September 16, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 89,864 | $21.98 | $1,975,489.30 |
DisclosureSEC source: 0000899243-21-036290 · doc4.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,628,522 F5 · shares: This acquisition of a total of 89,864 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F6 · price: The transaction was executed in multiple trades ranging from $21.45 to $22.39 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F7 · ownership.nature: Sumitovant directly owns 49,628,522 shares of Common Stock following the acquisition on September 15, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 6,172 | $22.76 | $140,446.95 |
DisclosureSEC source: 0000899243-21-036290 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,538,658 F1 · shares: This acquisition of a total of 71,300 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F4 · price: The transaction was executed in multiple trades ranging from $22.64 to $22.89 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,538,658 shares of Common Stock following the acquisition on September 14, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 65,128 | $22.04 | $1,435,238.76 |
DisclosureSEC source: 0000899243-21-036290 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,532,486 F1 · shares: This acquisition of a total of 71,300 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $21.55 to $22.48 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,538,658 shares of Common Stock following the acquisition on September 14, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 30,028 | $23.91 | $717,990.50 |
DisclosureSEC source: 0000899243-21-035821 · doc4.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,467,358 F4 · shares: This acquisition of a total of 83,178 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F7 · price: The transaction was executed in multiple trades ranging from $23.74 to $24.44 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,467,358 shares of Common Stock following the acquisition on September 13, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 53,150 | $23.09 | $1,227,058.11 |
DisclosureSEC source: 0000899243-21-035821 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,437,330 F4 · shares: This acquisition of a total of 83,178 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $22.74 to $23.73 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,467,358 shares of Common Stock following the acquisition on September 13, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 30,000 | $25.11 | $753,390.00 |
DisclosureSEC source: 0000899243-21-035821 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,384,180 F1 · shares: This acquisition of a total of 30,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $24.70 to $25.44 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,384,180 shares of Common Stock following the acquisition on September 10, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 37,000 | $25.52 | $944,147.50 |
DisclosureSEC source: 0000899243-21-035564 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,354,180 F4 · shares: This acquisition of a total of 37,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $25.14 to $26.00 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,354,180 shares of Common Stock following the acquisition on September 9, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 21,902 | $25.74 | $563,663.30 |
DisclosureSEC source: 0000899243-21-035564 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,317,180 F1 · shares: This acquisition of a total of 21,902 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $25.26 to $26.23 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,317,180 shares of Common Stock following the acquisition on September 8, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 4,913 | $27.12 | $133,249.40 |
DisclosureSEC source: 0000899243-21-035342 · doc4.xml · nonDerivative · entry 4 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,295,278 F5 · shares: This acquisition of a total of 33,200 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F8 · price: The transaction was executed in multiple trades ranging from $26.81 to $27.35 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F7 · ownership.nature: Sumitovant directly owns 49,295,278 shares of Common Stock following the acquisition on September 7, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 28,287 | $26.08 | $737,679.70 |
DisclosureSEC source: 0000899243-21-035342 · doc4.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,290,365 F5 · shares: This acquisition of a total of 33,200 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F6 · price: The transaction was executed in multiple trades ranging from $25.79 to $26.76 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F7 · ownership.nature: Sumitovant directly owns 49,295,278 shares of Common Stock following the acquisition on September 7, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 1,378 | $27.29 | $37,609.89 |
DisclosureSEC source: 0000899243-21-035342 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,262,078 F1 · shares: This acquisition of a total of 31,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F4 · price: The transaction was executed in multiple trades ranging from $27.25 to $27.32 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,262,078 shares of Common Stock following the acquisition on September 3, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 29,822 | $26.74 | $797,383.62 |
DisclosureSEC source: 0000899243-21-035342 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,260,700 F1 · shares: This acquisition of a total of 31,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $26.19 to $27.18 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,262,078 shares of Common Stock following the acquisition on September 3, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 5,848 | $26.95 | $157,631.09 |
DisclosureSEC source: 0000899243-21-035135 · doc4.xml · nonDerivative · entry 4 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,230,878 F4 · shares: This acquisition of a total of 63,102 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F8 · price: The transaction was executed in multiple trades ranging from $26.91 to $27.00 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,230,878 shares of Common Stock following the acquisition on September 2, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 35,045 | $26.46 | $927,388.83 |
DisclosureSEC source: 0000899243-21-035135 · doc4.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,225,030 F4 · shares: This acquisition of a total of 63,102 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F7 · price: The transaction was executed in multiple trades ranging from $25.90 to $26.89 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,230,878 shares of Common Stock following the acquisition on September 2, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 22,209 | $25.25 | $560,872.75 |
DisclosureSEC source: 0000899243-21-035135 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,189,985 F4 · shares: This acquisition of a total of 63,102 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $24.85 to $25.80 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,230,878 shares of Common Stock following the acquisition on September 2, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 40,000 | $24.83 | $993,028.00 |
DisclosureSEC source: 0000899243-21-035135 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,167,776 F1 · shares: This acquisition of a total of 40,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $24.33 to $24.99 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,167,776 shares of Common Stock following the acquisition on September 1, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 39,000 | $24.28 | $946,884.90 |
DisclosureSEC source: 0000899243-21-034765 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,127,776 F4 · shares: This acquisition of a total of 39,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $23.79 to $24.59 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,127,776 shares of Common Stock following the acquisition on August 31, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $23.92 | $1,674,099.00 |
DisclosureSEC source: 0000899243-21-034765 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,088,776 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $23.51 to $24.00 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,088,776 shares of Common Stock following the acquisition on August 30, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 37,038 | $23.17 | $858,251.94 |
DisclosureSEC source: 0000899243-21-034525 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,018,776 F4 · shares: This acquisition of a total of 37,038 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $22.61 to $23.51 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 49,018,776 shares of Common Stock following the acquisition on August 27, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 40,000 | $22.67 | $906,912.00 |
DisclosureSEC source: 0000899243-21-034525 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,981,738 F1 · shares: This acquisition of a total of 40,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $22.39 to $23.06 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 48,981,738 shares of Common Stock following the acquisition on August 26, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 28,709 | $22.44 | $644,158.19 |
DisclosureSEC source: 0000899243-21-034281 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,941,738 F4 · shares: This acquisition of a total of 28,709 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $22.00 to $22.55 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 48,941,738 shares of Common Stock following the acquisition on August 25, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 34,299 | $22.37 | $767,268.63 |
DisclosureSEC source: 0000899243-21-034281 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,913,029 F1 · shares: This acquisition of a total of 34,299 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $22.10 to $22.51 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 48,913,029 shares of Common Stock following the acquisition on August 24, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 30,390 | $22.45 | $682,322.36 |
DisclosureSEC source: 0000899243-21-034046 · doc4.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,878,730 F4 · shares: This acquisition of a total of 55,447 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F7 · price: The transaction was executed in multiple trades ranging from $22.36 to $22.66 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 48,878,730 shares of Common Stock following the acquisition on August 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 25,057 | $22.13 | $554,413.69 |
DisclosureSEC source: 0000899243-21-034046 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,848,340 F4 · shares: This acquisition of a total of 55,447 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $21.36 to $22.35 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 48,878,730 shares of Common Stock following the acquisition on August 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 46,478 | $20.86 | $969,540.38 |
DisclosureSEC source: 0000899243-21-034046 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,823,283 F1 · shares: This acquisition of a total of 46,478 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $20.32 to $21.27 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 48,823,283 shares of Common Stock following the acquisition on August 20, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 46,792 | $21.51 | $1,006,421.05 |
DisclosureSEC source: 0000899243-21-033840 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,776,805 F4 · shares: This acquisition of a total of 46,792 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F5 · price: The transaction was executed in multiple trades ranging from $21.13 to $21.87 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F6 · ownership.nature: Sumitovant directly owns 48,776,805 shares of Common Stock following the acquisition on August 19, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 21:00 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 17,116 | $21.45 | $367,091.99 |
DisclosureSEC source: 0000899243-21-033840 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,730,013 F1 · shares: This acquisition of a total of 17,116 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $21.06 to $21.72 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 48,730,013 shares of Common Stock following the acquisition on August 18, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 21:05 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 23,549 | $20.89 | $492,049.29 |
DisclosureSEC source: 0000899243-21-033476 · doc4.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,712,897 F5 · shares: This acquisition of a total of 23,549 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F6 · price: The transaction was executed in multiple trades ranging from $20.46 to $21.15 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F7 · ownership.nature: Sumitovant directly owns 48,712,897 shares of Common Stock following the acquisition on August 17, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76 % owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:05 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 5,382 | $21.94 | $118,089.69 |
DisclosureSEC source: 0000899243-21-033476 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,689,348 F1 · shares: This acquisition of a total of 48,167 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F4 · price: The transaction was executed in multiple trades ranging from $21.84 to $22.08 per share. The price reported above reflects the weighted average purchase price. The Reporting Person herereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 48,689,348 shares of Common Stock following the acquisition on August 16, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76 % owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:05 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 42,785 | $21.29 | $911,055.23 |
DisclosureSEC source: 0000899243-21-033476 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,683,966 F1 · shares: This acquisition of a total of 48,167 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). F2 · price: The transaction was executed in multiple trades ranging from $20.83 to $21.82 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 48,689,348 shares of Common Stock following the acquisition on August 16, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76 % owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 20, 2020 Filed May 21, 2020 17:25 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 37,897 | $12.58 | $476,861.74 |
DisclosureSEC source: 0000899243-20-013825 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,641,181 F4 · shares: This acquisition of a total of 37,897 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,641,181 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 19, 2020 Filed May 21, 2020 17:25 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $12.10 | $605,050.00 |
DisclosureSEC source: 0000899243-20-013825 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,603,284 F1 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,603,284 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 18, 2020 Filed May 19, 2020 19:13 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 35,000 | $12.36 | $432,624.50 |
DisclosureSEC source: 0000899243-20-013546 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,553,284 F4 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,553,284 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 15, 2020 Filed May 19, 2020 19:13 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 49,812 | $12.12 | $603,965.52 |
DisclosureSEC source: 0000899243-20-013546 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,518,284 F1 · shares: This acquisition of a total of 49,812 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,518,284 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 14, 2020 Filed May 15, 2020 19:28 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $12.02 | $600,760.00 |
DisclosureSEC source: 0000899243-20-013205 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,468,472 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,468,472 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.